Medable, a provider of clinical development technology, has announced a collaboration with Google Cloud to bring its decentralized clinical trial platform to Google Cloud Marketplace, a digital store for third-party software solutions. This partnership will allow customers to benefit from cutting-edge technology of Google’s cloud infrastructure and artificial intelligence (AI) capabilities.
“This alliance provides life sciences companies with Medable’s cutting-edge clinical development technology powered by Google Cloud through Google Cloud Marketplace,” said Michelle Longmire, co-founder and CEO of Medable.
“The collaboration will enable scaled and seamless adoption of Medable solutions by Google Cloud users, providing life sciences companies with platform capabilities proven to improve patient access to trials and accelerate critical development efforts, globally.”
Medable’s platform will be seamlessly integrated with Google Cloud Marketplace, which will enable users to access Medable’s recently launched Studio, a software as a service (SaaS) solution designed to provide pharmaceutical companies control and transparency in clinical trial design, execution, and data management.
“Bringing Medable’s platform to Google Cloud Marketplace will help customers quickly deploy, manage, and expand their use of the AI-driven clinical trial platform on Google Cloud’s trusted, global infrastructure,” said Dai Vu, managing director of Marketplace & Independent Software Vendor Go-To-Market Programs at Google Cloud.
Medable was founded in 2015 with the goal of enhancing speed scale and patient access in clinical research, accelerating the development of new therapies. The company’s software-as-a-service platform has been deployed in more than 300 decentralized and hybrid clinical trials across 60 countries, serving over one million participants.
The California-based company has reported 200% faster enrollment and 50% cost reductions thanks to the implementation of the platform. A previous study showed that decentralized clinical trials can achieve net financial benefits of 5 times for phase 2 clinical trials and 14 times when it comes to phase 3 trials.
The study, conducted by Medable in collaboration with the Tufts Center for the Study of Drug Development (CSDD) at the Tufts University School of Medicine in Boston, Massachusetts, employed data from more than 150 decentralized clinical trials enabled by Medable software. The financial returns were mainly driven by shorter development times, lower screening failure rates and fewer clinical trial protocol amendments.
“Medable was founded to create a more equitable system for medical research, to make trials more accessible and inclusive, and to solve systemic challenges inherent in modern clinical trials,” Longmire stated at the time. “By showcasing the net benefits for drug developers and patients, this research validates decentralized trials as a critical innovation on the path to enabling effective therapies to reach patients faster.”
Tim Smith, chief technology officer at Medable, said: “We are proud to showcase our AI capabilities within the Medable platform and, through Studio, eliminate one of the biggest hurdles to broad adoption of digital and decentralized clinical trials.
“Studio is just the start of an aggressive roadmap rolling out in 2025 as we continue to transform the way clinical research is conducted.”
